[go: up one dir, main page]

CL2012002087A1 - Metodo intracelular de conversion de una proteina de cadena simple de toxina de clostridium, en su forma dicatenaria. - Google Patents

Metodo intracelular de conversion de una proteina de cadena simple de toxina de clostridium, en su forma dicatenaria.

Info

Publication number
CL2012002087A1
CL2012002087A1 CL2012002087A CL2012002087A CL2012002087A1 CL 2012002087 A1 CL2012002087 A1 CL 2012002087A1 CL 2012002087 A CL2012002087 A CL 2012002087A CL 2012002087 A CL2012002087 A CL 2012002087A CL 2012002087 A1 CL2012002087 A1 CL 2012002087A1
Authority
CL
Chile
Prior art keywords
conversion
dicarious
single chain
clostridium toxin
chain protein
Prior art date
Application number
CL2012002087A
Other languages
English (en)
Inventor
Sanjiv Ghanshani
Linh Q Le
Yi Lui
Lance E Steward
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2012002087A1 publication Critical patent/CL2012002087A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Método de intracelular de conversión de toxina de clostridium de cadena simple que comprende una región de bucle dicatenario en su forma dicatenaria.
CL2012002087A 2010-01-25 2012-07-25 Metodo intracelular de conversion de una proteina de cadena simple de toxina de clostridium, en su forma dicatenaria. CL2012002087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28696310P 2010-01-25 2010-01-25

Publications (1)

Publication Number Publication Date
CL2012002087A1 true CL2012002087A1 (es) 2013-01-11

Family

ID=44146329

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002087A CL2012002087A1 (es) 2010-01-25 2012-07-25 Metodo intracelular de conversion de una proteina de cadena simple de toxina de clostridium, en su forma dicatenaria.

Country Status (23)

Country Link
US (3) US8546108B2 (es)
EP (3) EP2684890B1 (es)
JP (2) JP5956350B2 (es)
KR (1) KR101930962B1 (es)
CN (1) CN102822196B (es)
AU (1) AU2016204285B2 (es)
BR (1) BR112012018526A2 (es)
CA (1) CA2788074C (es)
CL (1) CL2012002087A1 (es)
CY (2) CY1115341T1 (es)
DK (1) DK2528940T3 (es)
ES (2) ES2592856T3 (es)
HU (1) HUE029962T2 (es)
IL (2) IL221095A (es)
MX (1) MX2012008650A (es)
NZ (1) NZ601472A (es)
PL (2) PL2528940T3 (es)
PT (2) PT2684890T (es)
RU (1) RU2569185C2 (es)
SG (1) SG182691A1 (es)
SI (2) SI2528940T1 (es)
WO (1) WO2011091370A1 (es)
ZA (1) ZA201205793B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546108B2 (en) * 2010-01-25 2013-10-01 Allergan, Inc. Methods of intracellular conversion of single-chain proteins into their di-chain form
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
WO2012123370A1 (en) * 2011-03-11 2012-09-20 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
CN104870468B (zh) 2012-11-21 2020-11-10 益普生生物创新有限公司 用于制备经蛋白水解处理的多肽的方法
JP6601922B2 (ja) 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
RU2627181C2 (ru) * 2015-12-29 2017-08-03 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Экспрессионный плазмидный лентивирусный вектор для гетерологичной экспрессии рекомбинантного человеческого белка cd47
BR112019010250A2 (pt) * 2016-11-22 2019-09-17 Klotho Therapeutics Inc novas proteínas klotho recombinantes e composições e métodos que envolvem as mesmas
US10308927B2 (en) * 2017-01-17 2019-06-04 The United States of America, as Represented by the Secretary of Homeland Security Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
CN109055339B (zh) * 2018-09-19 2020-09-01 生工生物工程（上海）股份有限公司 Tev蛋白酶突变体、基因、生物材料、制备方法、试剂或试剂盒和应用
JP7386552B2 (ja) * 2018-10-10 2023-11-27 上饒市康可得生物科技有限公司 プロテアーゼバリアントのスクリーニング方法および得られたプロテアーゼバリアント
CN111019926B (zh) * 2018-10-10 2021-11-26 上饶市康可得生物科技有限公司 Tev蛋白酶变体、其融合蛋白及制备方法和用途
CN111019925B (zh) * 2018-10-10 2022-08-23 上饶市康可得生物科技有限公司 筛选蛋白酶变体的方法以及获得的蛋白酶变体
WO2020073554A1 (zh) * 2018-10-10 2020-04-16 上饶市康可得生物科技有限公司 Tev蛋白酶变体、其融合蛋白及制备方法和用途
KR20200080749A (ko) * 2018-12-27 2020-07-07 주식회사 폴루스 N-말단의 메티오닌이 절단된 목적 단백질 발현용 유전자 발현 카세트 및 이를 이용하여 n-말단의 메티오닌이 절단된 목적 단백질을 생산하는 방법
JP6867452B2 (ja) * 2019-08-09 2021-04-28 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
WO2021062063A1 (en) * 2019-09-26 2021-04-01 Chan Zuckerberg Biohub, Inc. Improved variants of tev protease for biotechnological applications
CN113801866B (zh) * 2021-09-02 2022-08-16 无锡佰翱得生物科学有限公司 一种高效表达具有高活性及稳定性的重组tev酶及其制备方法和应用
CN115896132B (zh) * 2022-04-13 2025-03-28 中国农业科学院植物保护研究所 一种小麦矮腥黑粉菌效应蛋白基因
AU2023272468A1 (en) 2022-05-14 2024-11-14 Novonesis Plant Biosolutions A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4321618A1 (en) * 2022-08-09 2024-02-14 NUMAFERM GmbH Variants of tev protease and uses thereof
CN116640196B (zh) * 2023-05-10 2024-02-06 山东农业大学 囊泡相关膜蛋白的相关蛋白vap1在抗马铃薯y病毒中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180529T3 (es) 1990-02-26 2003-02-16 Univ Leland Stanford Junior Identificacion y expresion de secuencias de adn de un receptor de esteroides de insectos.
EP0745121B1 (en) 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US6746859B1 (en) 1993-01-15 2004-06-08 Genetics Institute, Llc Cloning of enterokinase and method of use
WO1994016083A1 (en) 1993-01-15 1994-07-21 Genetics Institute, Inc. Cloning of enterokinase and method of use
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
BR0012693A (pt) 1999-07-22 2002-04-09 Procter & Gamble Variante, de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal
JP2003507073A (ja) 1999-08-25 2003-02-25 アラーガン・セイルズ・インコーポレイテッド 活性化可能な組換え神経毒
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7132529B2 (en) 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US7022329B2 (en) 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
US6836976B2 (en) 2003-03-18 2005-01-04 Solveig Laura Haugland Collapsible outdoor footwear and backpack
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7825233B2 (en) 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
CA2575994A1 (en) 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
EP1982996A1 (en) 2004-09-01 2008-10-22 Allergan, Inc. Degradable clostridial toxins
US20060099710A1 (en) * 2004-11-10 2006-05-11 Donnelly Mark I Vector for improved in vivo production of proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
WO2006101809A1 (en) * 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
EP1996178A2 (en) 2006-03-17 2008-12-03 Andover Healthcare, Inc. Organotellurium and selenium-based antimicrobial antimicrobial formulations and articles
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP1897887A1 (de) * 2006-09-08 2008-03-12 Universitätsklinikum Freiburg Split-Core-Partikel für die Präsentation von Fremdmolekülen, insbesondere für Impfstoffanwendungen und Verfahren zu deren Herstellung
JP5404411B2 (ja) * 2006-11-22 2014-01-29 ノボ・ノルデイスク・エー／エス 活性化カルボキシペプチダーゼの製造方法
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
US20110306751A1 (en) * 2008-10-04 2011-12-15 University Of Medicine And Dentistry Of New Jersey Independently Inducible System of Gene Expression
US8546108B2 (en) * 2010-01-25 2013-10-01 Allergan, Inc. Methods of intracellular conversion of single-chain proteins into their di-chain form

Also Published As

Publication number Publication date
EP2528940B1 (en) 2014-05-14
US20120295330A1 (en) 2012-11-22
MX2012008650A (es) 2012-11-23
RU2012136227A (ru) 2014-03-10
JP5956350B2 (ja) 2016-07-27
CN102822196B (zh) 2014-12-17
DK2528940T3 (da) 2014-07-14
CY1117797T1 (el) 2017-05-17
AU2016204285B2 (en) 2018-03-29
IL246310A0 (en) 2016-07-31
US9340813B2 (en) 2016-05-17
AU2011207445A1 (en) 2012-08-30
US20140030759A1 (en) 2014-01-30
US8546108B2 (en) 2013-10-01
ES2488217T3 (es) 2014-08-26
JP6312745B2 (ja) 2018-04-18
CN102822196A (zh) 2012-12-12
PL2684890T3 (pl) 2016-11-30
EP2528940A1 (en) 2012-12-05
HK1179634A1 (en) 2013-10-04
US9938514B2 (en) 2018-04-10
NZ601472A (en) 2013-08-30
US20160319265A1 (en) 2016-11-03
SG182691A1 (en) 2012-08-30
KR20120134117A (ko) 2012-12-11
RU2569185C2 (ru) 2015-11-20
BR112012018526A2 (pt) 2020-09-08
IL221095A (en) 2017-06-29
EP2684890B1 (en) 2016-04-20
SI2684890T1 (sl) 2016-10-28
CY1115341T1 (el) 2017-01-04
CA2788074C (en) 2016-07-12
IL246310B (en) 2018-11-29
AU2016204285A1 (en) 2016-07-14
EP3034511A1 (en) 2016-06-22
PT2684890T (pt) 2016-07-28
ZA201205793B (en) 2013-05-29
EP2684890A1 (en) 2014-01-15
JP2013517797A (ja) 2013-05-20
WO2011091370A1 (en) 2011-07-28
PT2528940E (pt) 2014-06-24
JP2016164205A (ja) 2016-09-08
PL2528940T3 (pl) 2014-10-31
SI2528940T1 (sl) 2014-07-31
HUE029962T2 (hu) 2017-04-28
CA2788074A1 (en) 2011-07-28
KR101930962B1 (ko) 2018-12-19
ES2592856T3 (es) 2016-12-01

Similar Documents

Publication Publication Date Title
CL2012002087A1 (es) Metodo intracelular de conversion de una proteina de cadena simple de toxina de clostridium, en su forma dicatenaria.
UY34404A (es) Anticuerpo estable unido a múltiples antígenos
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
UY34327A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan 4-hidrofenil-piruvato-dioxigenasa?.
IL252154A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
BR112014030278A2 (pt) anticorpo, e, composição.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
EA201290638A1 (ru) Соединения и способы
EP3702368C0 (en) ANTIGEN-BINDING MOLECULES PROMOTING ANTIGEN CLEARANCE
DK2989893T3 (da) Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde
CL2009000632S1 (es) Estacion para fumadores.
BR112013001033A2 (pt) processo de fabricação pela embalagem de injetáveis
UY33992A (es) Métodos para modificar la biosintesis de la lignina y mejorar la digestibilidad
BR112013005947A2 (pt) laminado, embalagem e método
CL2011002403S1 (es) Luminaria solar.
CL2009001973S1 (es) Mostrador.
UY4152Q (es) Batería
CL2012001192S1 (es) Botella.
UY34638A (es) Empaque normalizado y método para su elaboración.
TR200903176A1 (tr) Çoklu blister.
IT1404749B1 (it) Metodo crittografico per stabilire una chiave crittografica condivisa, e relativo metodo di comunicazione asimmetrica crittata.
EA201301355A1 (ru) Композиция и таблетка, содержащая ралтегравир
CL2015001302A1 (es) Metodo de preparacion de 2-alquil-1,2-bencisotiazolin-3-onas.
IT1398844B1 (it) Articolo assorbente con tampone, con struttura matriciale, e metodo per la sua fabbricazione.
CL2011001069S1 (es) Triciclo.